Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway

被引：35

作者：

Korpanty, Grzegorz ^{[1
]}

Smyth, Elizabeth ^{[1
]}

Sullivan, Laura A. ^{[2
]}

Brekken, Rolf A. ^{[2
,3
]}

Carney, Desmond N. ^{[1
]}

机构：

[1] Mater Misericordiae Univ Hosp, Dept Med Oncol, Dublin 7, Ireland

[2] Univ Texas SW Med Ctr Dallas, Div Surg Oncol, Dept Surg, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA

[3] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA

来源：

EXPERIMENTAL BIOLOGY AND MEDICINE | 2010年 / 235卷 / 01期

关键词：

lung cancer; angiogenesis; VEGF; antiangiogenesis; RECEPTOR TYROSINE KINASE; COOPERATIVE-ONCOLOGY-GROUP; SMALL-CELL; TUMOR ANGIOGENESIS; PHASE-II; PERMEABILITY FACTOR; FACTOR VEGF; BEVACIZUMAB; COMBINATION; CARBOPLATIN;

D O I：

10.1258/ebm.2009.009191

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

引用

页码：3 / 9

页数：7

共 57 条

[1] Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung [J].

Akeson, AL ;

Greenberg, JM ;

Cameron, JE ;

Thompson, FY ;

Brooks, SK ;

Wiginton, D ;

Whitsett, JA .

DEVELOPMENTAL BIOLOGY, 2003, 264 (02) :443-455

[2]

[Anonymous], DRUGS RD

[3] Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors [J].

Cabebe E. ;

Wakelee H. .

Current Treatment Options in Oncology, 2007, 8 (1) :15-27

[4] Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance [J].

Cao, Yihai ;

Zhong, Weide ;

Sun, Yan .

SEMINARS IN CANCER BIOLOGY, 2009, 19 (05) :338-343

[5] Lung cancer - Time to move on from chemotherapy [J].

Carney, DN .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :126-128

[6]

Decaussin M, 1999, J PATHOL, V188, P369

[7] Epidermal growth factor receptor in tumor angiogenesis [J].

Ellis, LM .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (05) :1007-+

[8] Osteonecrosis of the jaw related to bevacizumab [J].

Estilo, Cherry L. ;

Fornier, Monica ;

Farooki, Azeez ;

Carlson, Diane ;

Bohle, George, III ;

Huryn, Joseph M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4037-4038

[9] VEGF and the quest for tumour angiogenesis factors [J].

Ferrara, N .

NATURE REVIEWS CANCER, 2002, 2 (10) :795-803

[10] Vascular endothelial growth factor: Basic science and clinical progress [J].

Ferrara, N .

ENDOCRINE REVIEWS, 2004, 25 (04) :581-611

← 1 2 3 4 5 6 →